Suraj Kalia
Stock Analyst at Oppenheimer
(3.63)
# 697
Out of 5,182 analysts
92
Total ratings
43.04%
Success rate
9.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Outperform | $132 → $115 | $92.80 | +23.92% | 3 | Apr 17, 2026 | |
| PRCT PROCEPT BioRobotics | Downgrades: Perform | n/a | $24.09 | - | 3 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Outperform | $150 → $175 | $108.12 | +61.86% | 12 | Feb 25, 2026 | |
| PODD Insulet | Maintains: Outperform | $365 → $300 | $188.31 | +59.31% | 1 | Feb 19, 2026 | |
| ATRC AtriCure | Downgrades: Perform | n/a | $29.04 | - | 8 | Feb 18, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $125 → $100 | $59.95 | +66.81% | 1 | Jan 16, 2026 | |
| INSP Inspire Medical Systems | Upgrades: Outperform | $175 | $55.07 | +217.78% | 3 | Dec 8, 2025 | |
| VREX Varex Imaging | Maintains: Outperform | $23 → $18 | $12.71 | +41.62% | 7 | Nov 19, 2025 | |
| EW Edwards Lifesciences | Downgrades: Perform | n/a | $83.46 | - | 6 | Oct 8, 2025 | |
| PLSE Pulse Biosciences | Initiates: Outperform | $22 | $22.65 | -2.87% | 1 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $120 | $125.96 | -4.73% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $37.03 | -13.58% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $90 → $93 | $114.52 | -18.79% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $4.50 | +122.22% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $3.00 | +333.33% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $135 | $85.35 | +58.17% | 1 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $222.02 | - | 6 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $24.24 | +23.76% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $320 → $200 | $0.49 | +40,959.33% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $70.48 | +37.63% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $21.41 | +30.78% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $5.48 | -17.88% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $0.81 | +1,885.36% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $470.99 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $1.86 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $18.49 | +440.83% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $61.41 | - | 5 | Sep 12, 2018 |
Abbott Laboratories
Apr 17, 2026
Maintains: Outperform
Price Target: $132 → $115
Current: $92.80
Upside: +23.92%
PROCEPT BioRobotics
Feb 26, 2026
Downgrades: Perform
Price Target: n/a
Current: $24.09
Upside: -
TransMedics Group
Feb 25, 2026
Maintains: Outperform
Price Target: $150 → $175
Current: $108.12
Upside: +61.86%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $365 → $300
Current: $188.31
Upside: +59.31%
AtriCure
Feb 18, 2026
Downgrades: Perform
Price Target: n/a
Current: $29.04
Upside: -
Boston Scientific
Jan 16, 2026
Maintains: Outperform
Price Target: $125 → $100
Current: $59.95
Upside: +66.81%
Inspire Medical Systems
Dec 8, 2025
Upgrades: Outperform
Price Target: $175
Current: $55.07
Upside: +217.78%
Varex Imaging
Nov 19, 2025
Maintains: Outperform
Price Target: $23 → $18
Current: $12.71
Upside: +41.62%
Edwards Lifesciences
Oct 8, 2025
Downgrades: Perform
Price Target: n/a
Current: $83.46
Upside: -
Pulse Biosciences
Jul 7, 2025
Initiates: Outperform
Price Target: $22
Current: $22.65
Upside: -2.87%
Jan 8, 2025
Maintains: Outperform
Price Target: $105 → $120
Current: $125.96
Upside: -4.73%
Nov 8, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $37.03
Upside: -13.58%
Nov 1, 2024
Reiterates: Outperform
Price Target: $90 → $93
Current: $114.52
Upside: -18.79%
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $4.50
Upside: +122.22%
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $3.00
Upside: +333.33%
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $85.35
Upside: +58.17%
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $222.02
Upside: -
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $24.24
Upside: +23.76%
Jun 23, 2023
Maintains: Outperform
Price Target: $320 → $200
Current: $0.49
Upside: +40,959.33%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $70.48
Upside: +37.63%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $21.41
Upside: +30.78%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $5.48
Upside: -17.88%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $0.81
Upside: +1,885.36%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $470.99
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $1.86
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $18.49
Upside: +440.83%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $61.41
Upside: -